Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.25 +0.79 (+4.49%)
Streaming Delayed Price Updated: 11:56 AM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Expert Outlook: Sarepta Therapeutics Through The Eyes Of 43 Analysts
 
Via Benzinga
2 Beaten-Down Stocks to Avoid Right Now
These once high-flying stocks no longer seem to have promising prospects. 
Via The Motley Fool
EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
Forecasting The Future: 44 Analyst Projections For Sarepta Therapeutics
 
Via Benzinga
This Pharma Stock Shot Up 8% Today, Gets A Price Target Hike From Wells Fargo: Here’s Why Retail Sees Opportunity
Via Stocktwits
Earnings Scheduled For August 6, 2025
 
Via Benzinga
What to Expect from Sarepta Therapeutics's Earnings
 
Via Benzinga
Sarepta Just Got A Good Restructuring Deal For $700M Debt, But Stock Tumbles 7% – Here’s Why
Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to certain investors as part of the deal. 
Via Stocktwits
What's Going On With Sarepta Shares Thursday?
 
Via Benzinga
Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients
The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys. 
Via Stocktwits
Topics Death
This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week
H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday. 
Via Stocktwits
Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives
Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquified its entire stake in the company. 
Via Investor's Business Daily
Topics Death
Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial
Sarepta sold part of its Arrowhead stake to help fund the milestone payment, while also outlining plans to release early data from two genetic therapy programs in the second half of 2025. 
Via Stocktwits
How Do Investors Really Feel About Sarepta Therapeutics?
 
Via Benzinga
Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside
Per two Wall Street analysts, one of 2025's biggest losers could be set up for a stunning recovery. They see over 175% upside in Sarepta Therapeutics. 
Via MarketBeat
Topics Death
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight. 
Via Benzinga
C3.ai, Destiny Tech100 And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Trump Ally Laura Loomer Calls Vinay Prasad A ‘Marxist Trojan Horse’ After FDA Rehiring, Slams NASA For Dropping Isaacman
Prasad resigned from the FDA in July after backlash over his handling of Sarepta’s Elevidys gene therapy, which faced shipment restrictions following patient deaths before being partially reinstated. 
Via Stocktwits
Topics Death Government
What 43 Analyst Ratings Have To Say About Sarepta Therapeutics
 
Via Benzinga
Dow Futures Rise As Trump’s Reciprocal Tariff Deadline Kicks In: AAPL, NVDA, INTC, LLY, SRPT Among Stocks To Watch
Via Stocktwits
Topics Government Stocks
Sarepta Therapeutics Inc (NASDAQ:SRPT) Surpasses Q2 2025 Estimates with Strong ELEVIDYS Performance
Sarepta Therapeutics (SRPT) surpasses Q2 2025 estimates with strong ELEVIDYS sales and Roche milestone payments, driving revenue growth and investor optimism. 
Via Chartmill
EXCLUSIVE: July's 20 Most-Searched Tickers On Benzinga Pro — Where Do Opendoor, Nvidia, Apple Stock Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
Trump Overrode RFK Jr. And Makary To Remove FDA Biologics Chief Amid Sarepta Drug Controversy: Report
The Trump administration is reportedly considering a major restructuring of the FDA’s biologics division, potentially splitting it into separate offices for vaccines and therapeutics. 
Via Stocktwits
Topics Death ETFs Government
REPL Stock Nearly Doubled In Value Today: What's Going On?
Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job. 
Via Stocktwits
This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Dow Futures Edge Up Ahead Of Fed Meeting, Big Tech Earnings: MSFT, META, F, HOOD, SRPT, SOFI Among Stocks To Watch
While Dow Jones futures were up 0.03% at the time of writing, the S&P 500 futures rose 0.1%. 
Via Stocktwits
Topics ETFs Economy Government
Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.